AGENUS INC: directors' dealings · United States · SEC (Form 4)

About AGENUS INC

Agenus Inc. (ticker: AGEN) is a clinical-stage biotechnology company listed on the Nasdaq Capital Market in the United States, with principal executive offices at 3 Forbes Road in Lexington, Massachusetts. The company was founded in 1994 by Garo H. Armen, who remains its Chairman and Chief Executive Officer. Agenus’ core mission has long been to broaden the population of patients who can benefit from cancer immunotherapy, and its operating model is built around internal discovery, translational research, clinical development, regulatory capabilities, and selective collaborations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf)) From an industry perspective, Agenus is not yet a commercial-stage pharma company with a mature marketed franchise; rather, it is a biotech focused on advancing next-generation immuno-oncology assets. Its lead clinical program is botensilimab (BOT, AGEN1181), an Fc-enhanced anti-CTLA-4 antibody, typically paired with balstilimab (BAL), a PD-1 inhibitor. That BOT/BAL combination is the centerpiece of the company’s strategy and is being studied across multiple solid-tumor settings, especially microsatellite-stable metastatic colorectal cancer, but also pancreatic cancer, melanoma, lung cancer and other tumor types. Agenus also has a broader pipeline including AGEN2373, AGEN1571, AGEN1777, AGEN1423 and AGEN1949, which gives the company a wider scientific footprint than many single-asset biotech peers. ([agenusbio.com](https://agenusbio.com/pipeline/)) Agenus competes in one of the most crowded and capital-intensive segments of biotech. The company explicitly notes competition from large pharmaceutical companies and emerging biotechnology peers across PD-1/PD-L1, CTLA-4, LAG-3, TIM-3, CD73, CD137 and TIGIT programs. In other words, the investment case hinges less on current revenues and more on clinical validation, durability of response, and the ability to secure partnerships or future commercialization pathways. BOT/BAL is therefore the key value driver, while the rest of the pipeline provides optionality. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf)) Geographically, Agenus is primarily a United States company, with manufacturing, R&D and corporate activities in Lexington, Massachusetts, plus corporate office space in New York and a California facility for cGMP manufacturing development. It also works through a global clinical footprint and multiple external collaborations. Recent highlights include management’s strategic realignment announced in late 2024, which prioritized the BOT/BAL program and paused certain non-core activities, as well as continued 2025-2026 updates on clinical data, the phase III BATTMAN study, and a strategic collaboration with Zydus Lifesciences aimed at advancing BOT/BAL and strengthening U.S. manufacturing readiness. For investors, AGEN remains a high-risk, event-driven biotech whose valuation is likely to be driven by trial readouts, partnership execution, and balance-sheet considerations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098972/000119312526197554/agen-ars-2025.pdf))